Elevated levels of circulating osteopontin are associated with a poor survival after resection of cholangiocarcinoma

Loosen, Sven H.; Roderburg, Christoph; Kauertz, Katja L.; Pombeiro, Ines; Leyh, Catherine; Benz, Fabian; Vucur, Mihael; Longerich, Thomas; Koch, Alexander; Braunschweig, Till; Ulmer, Tom Florian; Heidenhain, Christoph; Tacke, Frank; Binnebösel, Marcel; Schmeding, Maximilian; Trautwein, Christian; Neumann, Ulf; Luedde, Tom

doi:10.1016/j.jhep.2017.06.020

Cited by 67 publications

(54 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Serum levels of SIBLINGs were recently identified as prognostic markers for different diseases [7][8][9]. Based on these data, we next aimed at analyzing whether BSP concentrations are suitable to predict mortality in patients with liver cirrhosis.…”

Section: No Association Between Bsp Serum Concentrations With Patientmentioning

confidence: 99%

See 1 more Smart Citation

Serum levels of bone sialoprotein correlate with portal pressure in patients with liver cirrhosis

et al. 2020

Self Cite

View full text Add to dashboard Cite

Liver cirrhosis represents the common end-stage of chronic liver diseases regardless of its etiology. Patients with compensated disease are mostly asymptomatic, however, progression to a decompensated disease stage is common. The available stratification strategies are often unsuitable to identify patients with a higher risk for disease progression and a limited prognosis. SIBLINGs, soluble glycophosphoproteins, are secreted into the blood by immune-cells. While osteopontin, the most prominent member of the SIBLINGs family, has been repeatedly associated with liver cirrhosis, data on the diagnostic and/or prognostic value of bone sialoprotein (BSP) are scarce and partly inconclusive. In this study, we analyzed the diagnostic and prognostic potential of circulating BSP in comparison to other standard laboratory markers in a large cohort of patients with liver cirrhosis receiving transjugular intrahepatic portosystemic shunt (TIPS). Serum levels of BSP were similar in patients with different disease stages and were not indicative for prognosis. Interestingly, BSP serum levels did correlate inversely with portal pressure, as well as its surrogates such as platelet count, the portal vein cross-sectional area and correlated positively with the portal venous velocity. In summary, our data highlight that BSP might represent a previously unrecognized marker for portal hypertension in patients with liver cirrhosis.

show abstract

Section: No Association Between Bsp Serum Concentrations With Patientmentioning

confidence: 99%

“…SIBLINGs regulate a plethora of processes such as cell death, angiogenesis and ECM remodeling. In line, SIBLINGs have been proposed as biomarkers for different diseases including inflammatory and infectious diseases as well as cancers [7][8][9][10][11][12][13][14].…”

Section: Introductionmentioning

confidence: 99%

Serum levels of bone sialoprotein correlate with portal pressure in patients with liver cirrhosis

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…In our study, the diagnostic power of osteopontin was superior to CEA and CA19–9. Notably, circulating levels of osteopontin were also significantly higher in CCA patients compared to PSC patients [56]. …”

Section: Resultsmentioning

confidence: 99%

“…In a large cohort of 107 patients with CCA and who underwent elective tumour resection, we recently demonstrated that serum levels of osteopontin are elevated in patients with CCA compared to healthy controls as well as compared to patients with primary sclerosing cholangitis. In this cohort, pre- and postoperative elevations of osteopontin were associated with an impaired patients’ prognosis and indicated poor postoperative survival [56]. Thus, analysis of osteopontin serum levels might not only help to predict overall survival of patients with resectable CCA but also to specifically identify patients who particularly benefit from extended liver surgery.…”

Section: Resultsmentioning

confidence: 99%

Circulating Biomarkers for Cholangiocarcinoma

Loosen

Vucur

Roderburg

et al. 2018

Dig Dis

Self Cite

View full text Add to dashboard Cite

Background: Cholangiocarcinoma (CCA) represents the second most common primary liver malignancy. The incidence rate has constantly increased over the last decades and CCA patients face a dismal prognosis with a 5-year survival rate of less than 5% for advanced stage of disease. Surgical tumor resection has remained the only potentially curative treatment option in daily practice but is often not feasible due to advanced disease stage at initial diagnosis. Summary: The early detection of cholangiocarcinoma is essential to provide patients with a potentially curative treatment. Furthermore, prognostic biomarkers represent a valuable tool to offer patients a tailored therapeutic approach in accordance to their life expectancy. The clinically most established biomarker carbohydrate antigen 19–9 shows only a limited diagnostic and prognostic power, encouraging the evaluation of novel biomarkers for cholangiocarcinoma in the last years. Key Massage: In this review, we assess currently available and potential future biomarkers for the diagnosis and prognosis of cholangicarcinoma.

show abstract

“…Circulating osteopontin, a secreted glycol phosphoprotein, is also elevated in CCA patients compared to healthy controls or patients with PSC. It is important to note that high pre‐ and post‐operative osteopontin levels were associated with reduced overall survival after tumour resection …”

Section: Non‐invasive Biomarkersmentioning

confidence: 99%

Diagnostic and prognostic biomarkers in cholangiocarcinoma

Macı́as

Kornek

Rodrigues

et al. 2019

Liver International

Self Cite

View full text Add to dashboard Cite

The high mortality rate of cholangiocarcinoma (CCA) is due, in part, to the lack of non‐invasive approaches able to accurately detect this silent tumour at early stages, when therapeutic options can be potentially curative or may at least increase the overall survival of patients. The fact that the majority of CCA tumours are not linked to any known aetiological factor highly compromises the monitoring of patients at risk for tumour development and also their early diagnosis. Combination of clinical/biochemical features, imaging techniques and analysis of non‐specific tumour biomarkers in serum are commonly used to help in the diagnosis of CCA, but tumour biopsy is usually required to confirm the diagnosis. Moreover, no prognostic biomarkers are currently used in the clinical setting, deserving more innovative research, and international validation and consensus. Important efforts have been made in the last few years to identify accurate non‐invasive biomarkers, by using innovative techniques and high‐throughput omics technologies. This review summarizes and discusses the advances in the investigation of novel diagnostic and prognostic biomarkers in CCA and envisions the future directions in this field of research.

show abstract

Elevated levels of circulating osteopontin are associated with a poor survival after resection of cholangiocarcinoma

Cited by 67 publications

References 39 publications

Serum levels of bone sialoprotein correlate with portal pressure in patients with liver cirrhosis

Serum levels of bone sialoprotein correlate with portal pressure in patients with liver cirrhosis

Circulating Biomarkers for Cholangiocarcinoma

Diagnostic and prognostic biomarkers in cholangiocarcinoma

Contact Info

Product

Resources

About